Open Access

Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer

  • Authors:
    • Jin Zhu
    • Peibo Qin
    • Cheng Cao
    • Guangcheng Dai
    • Lijun Xu
    • Dongrong Yang
  • View Affiliations

  • Published online on: January 5, 2021     https://doi.org/10.3892/or.2021.7925
  • Pages: 963-974
  • Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The human testicular nuclear receptor 4 (TR4) is a critical regulatory gene for the progression of prostate cancer (PCa). Although it has been revealed that TR4 causes chemoresistance in PCa via the activation of octamer‑binding transcription factor 4 (OCT4), the detailed mechanism remains unexplored. In the present study, it was revealed that inhibition of TR4 by shRNA in PCa enhanced the sensitivity to docetaxel in vitro and in vivo. TR4 induced the downregulation of miR‑145 by directly binding it to the promoter of miR‑145, which was confirmed by chromatin immunoprecipitation analysis and luciferase assay. The overexpression of miR‑145 suppressed both the chemoresistance and the expression of OCT4 mRNA and protein. Additionally, the TR4 shRNA mediated re‑sensitization to docetaxel, along with the downregulated expression of OCT4, were reversed by the concurrent inhibition of miR‑145. The luciferase assay revealed that the activity of the wild‑type OCT4 3' untranslated region reporter was suppressed. This suppression diminished when the miR‑145 response element mutated. These findings suggest an undescribed regulatory pathway in PCa, by which TR4 directly suppressed the expression of miR‑145, thereby inhibiting its direct target OCT4, leading to the promotion of chemoresistance in PCa.
View Figures
View References

Related Articles

Journal Cover

March-2021
Volume 45 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhu J, Qin P, Cao C, Dai G, Xu L and Yang D: Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer. Oncol Rep 45: 963-974, 2021
APA
Zhu, J., Qin, P., Cao, C., Dai, G., Xu, L., & Yang, D. (2021). Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer. Oncology Reports, 45, 963-974. https://doi.org/10.3892/or.2021.7925
MLA
Zhu, J., Qin, P., Cao, C., Dai, G., Xu, L., Yang, D."Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer". Oncology Reports 45.3 (2021): 963-974.
Chicago
Zhu, J., Qin, P., Cao, C., Dai, G., Xu, L., Yang, D."Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer". Oncology Reports 45, no. 3 (2021): 963-974. https://doi.org/10.3892/or.2021.7925